<DOC>
	<DOCNO>NCT00469833</DOCNO>
	<brief_summary>The objective project understand defect insulin secretion contribute abnormal glucose metabolism patient diabetes . In particular effect signal release intestine stimulate insulin secretion test . Patients type 2 diabetes insulin secretion response glucose intestinal factor insulin treatment low blood glucose . It expect result work provide valuable information treat diabetic people .</brief_summary>
	<brief_title>Insulin Secretion Diabetes Before After Glycemic Control</brief_title>
	<detailed_description>The objective project understand defect insulin secretion contribute abnormal glucose metabolism patient diabetes . Diabetes major problem patient receive care VA medical center among 20 % affected . Specifically , project seek determine mechanism ( ) incretin effect impaired diabetic patient . The incretin effect refers action GI hormones neural stimulus increase insulin secretion food intake , account approximately 50 % postprandial insulin secretion nondiabetic human . There several study indicate response severely impaired patient type 2 diabetes . The mechanism ( ) occurs explain . There evidence suggest secretion important incretins , glucagon-like peptide 1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) , may impair diabetic individual . There also data suggest beta-cells person diabetes insensitive incretins . The problem current state knowledge area previous work involve small number diabetic subject , directly test mechanism incretin effect alter diabetes . In project determine role hyperglycemia impair incretin effect . Type 2 diabetic subject incretin effect measure intensified diabetes treatment . This study test effect chronic hyperglycemia incretin mediate insulin secretion . In study , incretin effect measure intervention use study within subject design . A combined glucose clamp/meal tolerance test protocol use quantify incretin effect . These study allow role incretin secretion , incretin action , overall metabolic milieu , postprandial insulin secretion define . The result study add important new information understand abnormal beta-cell function diabetes . By identify site incretin effect impair project provide basis new approach treat diabetic patient . This especially relevant recent availability new medication target incretin pathway low blood glucose . The blood sample draw process GCRC . The sample freeze store Building 15 , Room 401 . Samples ship Genome Research Institute staff train IATA shipping procedure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Aim 1 : ( nondiabetics ) male/female 3065 yr old , free active medical disease , history diabetes . ( diabetic ) HbA1c=6.58.5 , treat metformin , sulfonylurea , combination , Stable body wt BMI 2840 . Aim 2 : Same Aim 3 : Diabetic HgA1c 8.09.5 Aim 1 : For group : history : pancreatitis , cardiac , gastrointestinal , renal liver disease . Aim 2 : Same Aim 3 : Same , plus diagnosis incipient diabetic nephropathy severe nonproliferative , proliferative retinopathy .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Glucose Tolerance</keyword>
	<keyword>Incretin</keyword>
	<keyword>Insulin</keyword>
</DOC>